AHA 2010 - Cardiology Conference Coverage

Heartwire

Clinical cardiology

ASCET: Single antiplatelet therapies compared in stable CAD

4 COMMENTS - Nov 26, 2010 12:48 EST

ASCET is the first study since CAPRIE to compare aspirin and clopidogrel as single antiplatelet therapy in patients with stable CAD; further, it used a platelet-function test to examine the interplay of aspirin responsiveness with treatment. The trial hints at better outcomes with clopidogrel in aspirin nonresponders.

Heart failure

Low levels of troponin predict HF, death in older adults

1 COMMENT - Nov 25, 2010 15:50 EST

A new study is the first to demonstrate that low levels of cardiac troponin T, as detected by a highly sensitive assay, are associated with new-onset heart failure and cardiovascular death in older individuals. But more research is needed to see whether tracking low levels of troponin in this population will be clinically useful, say the researchers.

Imaging

New registry CONFIRMs prognostic value of coronary CT angiography in symptomatic patients

14 COMMENTS - Nov 23, 2010 17:30 EST

New registry data show how coronary computed tomography angiography can be used to predict mortality risk more accurately than traditional risk factors in symptomatic patients.

Prevention

Canadian docs misclassifying two-thirds of patients at high risk for cardiovascular events

16 COMMENTS - Nov 23, 2010 11:45 EST

Canadian primary-care physicians are not accurately assessing cardiovascular risk in middle-aged adults, a particular concern for high-risk patients classified as low risk. The implications of the study are that a sizable proportion of these patients might not be prescribed lipid-lowering therapy, say researchers.

Heart failure

PROTECT: Adjust HF meds to achieve natriuretic-peptide targets

1 COMMENT - Nov 23, 2010 10:00 EST

Adjusting heart-failure medications with the goal of reducing natriuretic peptides to a prespecified level, which has produced mixed results in a number of small trials, significantly improved outcomes in yet another small study. A large multicenter randomized trial would be welcome, observers say.

Acute Coronary Syndromes

Patient and physician education program reduces STEMI-symptom-to-treatment time in Minnesota

Nov 22, 2010 17:30 EST

A networkwide effort to get patients with STEMI symptoms to come to the hospital faster is reducing the total time to reperfusion in Minnesota and offsetting some of the longer door-to-balloon times in rural areas.

Brain/Kidney/Peripheral

Xanthelasma linked with MI and ischemic heart disease

Nov 22, 2010 14:30 EST

The condition, which results in a yellowish collection of fatty cholesterol around the eyelids, is usually seen by family doctors and dermatologists but should serve a marker of underlying atherosclerotic disease, even in patients with normal cholesterol levels, say researchers.

Hypertension

Pass on pizza: Cutting salt by a third could halve hypertension among teens

Nov 22, 2010 12:00 EST

Teenagers eat the most salt of any age group in the US and as such represent a key target for sodium-reduction policies, with the adolescent years being "a window of opportunity" to set up lifelong good eating habits, say researchers. Cutting the amount of salt teens consume by a third could cut hypertension by half and reduce deaths at age 50 by almost 10%, they calculate.

Lipid/Metabolic

Coronary calcium weeds out JUPITER-like patients who will benefit from statins, beats CRP for risk prediction

48 COMMENTS - Nov 19, 2010 17:45 EST

Among MESA patients meeting criteria for statins based on JUPITER who have a high coronary artery calcium score, the risk of cardiovascular events is significantly greater than those without calcification, suggesting that calcium screening with computed tomography might be used to further stratify at-risk patients for statin therapy.

Heart failure

No dent in readmissions, mortality seen with telemonitoring-guided HF care

2 COMMENTS - Nov 18, 2010 17:45 EST

UPDATED WITH COMMENTARY // Heart-failure management guided by various remote-monitoring strategies has improved outcomes in mostly observational studies, not randomized trials. Now two such prospective, controlled trials suggest that telemonitoring doesn't cut the risk of hospitalizations or death, after all. Two expert observers declare the strategy all but dead.

Interventional/Surgery

Small TRITON substudy hints at better survival with prasugrel in CABG patients

Nov 18, 2010 13:00 EST

The improved survival signal was seen despite an increased risk of bleeding with prasugrel vs clopidogrel. At least one outside commentator is not convinced, saying the analysis is "highly confounded" and makes many assumptions.

Prevention

Disparities still exist post-healthcare reform in Massachusetts

1 COMMENT - Nov 18, 2010 11:00 EST

A new study indicates that disparities still exist in the invasive treatment of cardiovascular disease in Massachusetts, despite that state's Health Care Reform Act of 2006. Data from Australia, however, illustrate the success of a universal healthcare system.

Lipid/Metabolic

ASCOT analysis fuels debate over JUPITER-based CRP indication for statins

5 COMMENTS - Nov 18, 2010 10:00 EST

To CRP or not to CRP, that is the conundrum: the post hoc analysis found that there was little benefit from adding the biomarker to standard risk assessments. Or is there? A number of experts weigh in.

Medscape Medical News

ASSERT: Device-detected atrial tachyarrhythmias are common, raise stroke risk

1 COMMENT - Nov 17, 2010 17:45 EST

Device-detected arrhythmias in patients with pacemakers were associated with a 2.5-fold increase in the risk of ischemic stroke and systemic embolism. For patients with a CHADS₂ score >2, atrial tachyarrhythmias increased absolute stroke risk to 2% per year.

Lipid/Metabolic

Oral inducer of apoA-1 synthesis RVX-208 misses end point but provides reasons for optimism

Nov 17, 2010 16:30 EST

The ASSERT trial shows that the oral agent RVX-208 increases levels of apoA-1 and thereby mobilizes high-density lipoproteins, especially large alpha-1 HDL particles, but the trial did not meet its primary end point of increase in apoA-1 level vs placebo.

Lipid/Metabolic

DEFINE: Large effects on LDL and HDL cholesterol with CETP inhibitor anacetrapib

54 COMMENTS - Nov 17, 2010 09:00 EST

UPDATED WITH COMMENTARY // With the dramatic changes in LDL- and HDL-cholesterol levels and no apparent off-target blood pressure, electrolyte, and aldosterone effects, as well as no adverse safety signal that plagued torcetrapib, DEFINE investigators are optimistic about a larger morbidity and mortality trial with HDL-raising therapy. As one expert put it, "We've gone as far with statins as we can go."

Hypertension

A revolutionary road for resistant hypertension? Renal denervation in Symplicity HTN-2

5 COMMENTS - Nov 17, 2010 09:00 EST

UPDATED WITH COMMENTARY // The possibility of an interventional approach providing a successful treatment option for patients with resistant hypertension has edged nearer with the success of renal sympathetic denervation in the SYMPLICITY HTN-2 trial. Although the results will require confirmation, they raise the tantalizing possibility of a cure for hypertension.

Interventional/Surgery

Little to REVEAL: Adding EPO after PCI does not reduce infarct size

Nov 16, 2010 18:00 EST

With another negative erythropoietin trial, investigators are debating whether to give up on the investigational treatment or continue to look for ways to use EPO to reduce infarct size following successful PCI for STEMI.

Interventional/Surgery

BASKET-PROVE: DES as safe as bare-metal stents in larger coronary arteries, with less TVR

5 COMMENTS - Nov 16, 2010 17:00 EST

In patients needing a coronary stent 3 mm in diameter or larger, drug-eluting stents do not increase the risk of late cardiac events compared with bare-metal stents, the results of BASKET-PROVE show.

Brain/Kidney/Peripheral

ACT: No benefit of N-acetylcysteine to reduce contrast-induced nephropathy

6 COMMENTS - Nov 16, 2010 15:00 EST

The findings, from the ACT trial, the largest randomized study to date, provide solid evidence that N-acetylcysteine is not effective in the angiography setting and should no longer be used for the prevention of contrast-induced nephropathy, according to investigators.

Brain/Kidney/Peripheral

TAMARIS: Gene therapy fails in phase 3 trial of critical limb ischemia

Nov 16, 2010 12:00 EST

The largest gene-therapy trial ever in critical limb ischemia has failed to show a significant benefit of this approach in these very sick patients. The findings, "which are definitely negative," emphasize the importance of properly conducted phase 3 trials, say the investigator and others.

Interventional/Surgery

GRAVITAS: No benefit of doubling dose in clopidogrel nonresponders

15 COMMENTS - Nov 16, 2010 09:00 EST

UPDATED WITH COMMENTARY // The disappointing results of this eagerly awaited study show an identical rate of the composite end point in both groups.

Interventional/Surgery

CICERO: Mixed results for intracoronary abciximab in STEMI

Nov 16, 2010 08:00 EST

Intracoronary rather than intravenous administration had differing effects on two measures of myocardial reperfusion, improving myocardial blush grade but not ST-segment resolution, the primary end point. Infarct size was also smaller in the intracoronary group, but any benefits could have been due to better artery patency at baseline.

Brain/Kidney/Peripheral

CLOSURE I: No overall benefit, no reduction in stroke or TIA with PFO closure

19 COMMENTS - Nov 15, 2010 17:45 EST

CORRECTED // The full final results, showing no impact of device closure on a composite end point of risk of stroke or TIA at two years, should prompt physicians to look harder for a true cause of cryptogenic strokes, rather than finding and closing a hole and assuming they've solved the problem.

Heart failure

SMART-AV: SmartDelay fails to outwit other CRT AV-delay-optimization approaches

Nov 15, 2010 17:00 EST

Neither the SmartDelay programming option nor echocardiography-guided AV delay produced superior results to fixed AV-delay programming in the SMART-AV cardiac resynchronization trial.

Interventional/Surgery

PARTNER quality-of-life analysis: Large and sustained benefits in TAVI group

1 COMMENT - Nov 15, 2010 16:45 EST

Given the advanced age and multiple comorbidities in inoperable aortic-stenosis patients, the finding of a large improvement in quality-of-life end points may be as "equally important" a finding as improved survival.

Thrombosis

New pharmacodynamic data confirm PLATO genetics substudy findings

Nov 15, 2010 16:45 EST

The first comparative clinical study of CYP2C19 genotype on ticagrelor pharmacodynamics shows that the new investigational antiplatelet agent is better at inhibiting platelet function than clopidogrel, irrespective of genotype or metabolizer status. The findings confirm the previous results of the PLATO pharmacogenetics substudy, say the researchers.

Medscape Medical News

Vitamin-D deficiency linked to fatal stroke in whites but not blacks

4 COMMENTS - Nov 15, 2010 13:45 EST

Using NHANES III data, researchers showed that although blacks are more likely to be vitamin-D deficient, that deficiency did not appear to affect the risk for fatal stroke, unlike in whites.

Acute Coronary Syndromes

Dueling advice: New ACC/AHA risk assessment guidelines, SHAPE II released on same day

2 COMMENTS - Nov 15, 2010 10:00 EST

The American College of Cardiology and American Heart Association release new guidelines on the assessment of cardiovascular risk in asymptomatic adults, while SHAPE draws attention to the planned revision of its screening guidelines.

Arrhythmia/EP

Omega-3 PUFA caps don't suppress paroxysmal AF in randomized trial

4 COMMENTS - Nov 15, 2010 09:45 EST

UPDATED WITH COMMENTARY // In a randomized trial, taking the Lovaza prescription form of fish-oil supplement at 4 g/day for six months didn't protect against symptomatic recurrences of paroxysmal atrial fibrillation.

Arrhythmia/EP

Off orbit? ROCKET AF: Rivaroxaban noninferior to warfarin, but superiority analyses at odds

8 COMMENTS - Nov 15, 2010 09:00 EST

UPDATED WITH COMMENTARY // ROCKET AF, as previously reported, met its primary end point of noninferiority, but one of two prespecified superiority analyses, the gold standard intention-to-treat, failed to show the drug was better than warfarin for the prevention of thromboembolic events in patients with nonvalvular AF. The second per-protocol on-treatment analysis, however, showed superiority.

Brain/Kidney/Peripheral

Give it some time! Plug pulled too soon in hypothermia-treated cardiac-arrest patients

Nov 14, 2010 18:30 EST

New data from multiple studies suggest that clinicians are pulling the plug too early in hypothermia-treated cardiac-arrest patients. One study suggests that 5% to 10% of these patients have a chance of surviving if clinicians give them more time than the arbitrary 72-hour cutoff.

Heart failure

ASCEND-HF: Nesiritide safe but of limited dyspnea benefit in acute HF

3 COMMENTS - Nov 14, 2010 17:45 EST

Five years ago, one of the biggest, most burning questions in cardiology was whether the once-popular IV vasodilator hurt or helped in acute decompensated heart failure. The trial designed to settle the issue now says no to the first and yes, but only a little bit to the second, in the short term.

Heart failure

ADVANCE: New LVAD equivalent to HeartMate II, nonrandomized study shows

Nov 14, 2010 16:35 EST

The ADVANCE study, looking at the use of a new, smaller, left ventricular assist device as a bridge to transplant, has shown that it is noninferior to the currently available LVAD, the HeartMate II. Although long-term data are needed, these early results are encouraging and suggest the new device is yet another option for such patients. And an ongoing head-to-head study of the two devices in the arena of destination therapy will also prove very interesting, say observers.

Heart failure

EMPHASIS-HF: Eplerenone shows large benefits in milder heart failure

4 COMMENTS - Nov 14, 2010 09:00 EST

UPDATED WITH COMMENTARY // The aldosterone antagonist produced large reductions in both the risk of death and the risk of hospitalization compared with placebo in patients with systolic heart failure and mild symptoms.

Heart failure

CRT is a lifeRAFT for class 2 and 3 HF patients with low EF and wide QRS

Nov 14, 2010 09:00 EST

The trial shows that cardiac resynchronization therapy provides a survival benefit over ICD alone in patients with NYHA class 2 or 3 heart failure, a wide QRS duration, and left ventricular systolic dysfunction.

Arrhythmia/EP

Familial atrial fib ups AF risk independent of known AF gene variants: Framingham

Nov 13, 2010 16:00 EST

For some people, it's something else to "blame" on mom, dad, brother, or sister, at least partly. The adjusted risk of developing atrial fibrillation went up 40% for those with a parent or sibling also with the arrhythmia.

Arrhythmia/EP

What's going to be hot at AHA 2010

2 COMMENTS - Nov 9, 2010 09:00 EST

This year's lineup of late-breaking trials includes some of the most eagerly anticipated trials of recent memory, looking at everything from nesiritide, rivaroxaban, and anacetrapib to platelet-function tests and CRP-guided therapy to PFO closure, renal sympathetic denervation, and a new nonpulsatile VAD.

Discussion and opinions

Blogs

The Bob Harrington Show

#32: Advances in heart-failure research with Dr Clyde Yancy

Jan 10, 2011 16:05 EST

Topolog

Symplicity: A key to treating severe resistant hypertension

Dec 03, 2010 11:20 EST

2 comments

Cutting-edge dialogues with Drs Tim Gardner and Mat Williams

Surgeons and interventionalists learn from PARTNER

Nov 29, 2010 16:15 EST

1 comments

Heart failure and transplantation with Dr Ileana Piña

Electronic health records: Bettering uptake and use

Nov 29, 2010 12:15 EST

This week in cardiology from heartwire

#67: SHARP: Ezetimibe/simvastatin in renal disease; APPRAISE-2 (apixaban) ACS trial halted; ASCOT analysis fuels debate...

Nov 26, 2010 14:55 EST

This week in cardiology from heartwire

#66: Top news from AHA 2010 - EMPHASIS-HF: Eplerenone benefits in milder HF; rivaroxaban...

Nov 19, 2010 14:05 EST

Private practice with Dr Seth Bilazarian

GRAVITAS has immediate impact on my practice

Nov 19, 2010 12:05 EST

2 comments

Trials and PIs

Oral Agent Inducing ApoA1 Synthesis with Dr Stephen Nicholls

Nov 17, 2010 14:42 EST

Trials and PIs

Symplicity HTN-2 with Dr Murray Esler

Nov 17, 2010 13:10 EST

1 comments

Trials and PIs

DEFINE with Dr Christopher Cannon

Nov 17, 2010 13:05 EST

10 comments

Heartfelt with Dr Melissa Walton-Shirley

DES safety in BASKET-PROVE; ACT on contrast-induced nephropathy; dosing for clopidogrel nonresponders in GRAVITAS; TAMARIS...

Nov 17, 2010 00:05 EST

Trials and PIs

ACT Trial with Dr Otavio Berwanger

Nov 16, 2010 18:32 EST

1 comments

Trials and PIs

BASKET PROVE with Dr Christoph Kaiser

Nov 16, 2010 16:09 EST

Trials and PIs

NV1FGF Gene Therapy on Amputation-Free Survival in Critical Limb Ischemia--Phase 3 Randomized Double-Blind Placebo-Controlled Trial...

Nov 16, 2010 16:01 EST

Trials and PIs

GRAVITAS with Dr Matthew Price

Nov 16, 2010 15:43 EST

Heart failure and transplantation with Dr Ileana Piña

Petitioning the Social Security Administration for compassionate disability for HF, transplant, and congenital heart-disease patients

Nov 16, 2010 15:30 EST

Heartfelt with Dr Melissa Walton-Shirley

Latest on atrial fibrillation with analysis of ROCKET AF (rivaroxaban) and POM 3 (fish oil...

Nov 16, 2010 10:40 EST

2 comments

Trials and PIs

ASCEND-HF with Dr Christopher O'Connor

Nov 16, 2010 09:53 EST

Trials and PIs

ADVANCE Bridge to Transplant Trial with Dr Keith Aaronson

Nov 16, 2010 09:48 EST

Private practice with Dr Seth Bilazarian

New horizons for atrial fibrillation as ROCKET AF (rivaroxaban) follows on the heels of RE-LY...

Nov 16, 2010 08:20 EST

Heartfelt with Dr Melissa Walton-Shirley

Take the thrombin-inhibitor exam: Automatically win a million dollars if you get 100% correct!

Nov 15, 2010 23:37 EST

3 comments

Trials and PIs

RAFT with Dr Anthony Tang

Nov 15, 2010 15:17 EST

Trials and PIs

Prescription Omega-3-Acid Ethyl Esters (P-OM3) for the Prevention of Recurrent Symptomatic Atrial Fibrillation (AF) with...

Nov 15, 2010 15:09 EST

1 comments

Trials and PIs

SMART AV with Dr Kenneth Ellenbogen

Nov 15, 2010 12:29 EST

Trials and PIs

ROCKET AF with Dr Kenneth Mahaffey

Nov 15, 2010 12:13 EST

1 comments

Heartfelt with Dr Melissa Walton-Shirley

Three decades worth of proof: Minnesota cities prove critics of smoking-cessation efforts wrong, wrong, WRONG!

Nov 15, 2010 08:04 EST

5 comments

Heartfelt with Dr Melissa Walton-Shirley

Results, analysis, and clinical implications of leading heart-failure trials at AHA 2010: Eplerenone in EMPHASIS-HF;...

Nov 14, 2010 23:15 EST

Private practice with Dr Seth Bilazarian

Eplerenone, nesiritide, CRT, LVAD: Clinical implications of heart-failure trial results from AHA 2010

Nov 14, 2010 22:30 EST

Heartfelt with Dr Melissa Walton-Shirley

Faith and nesiritide: "The substance of things hoped for. The evidence of things not seen."

Nov 14, 2010 16:29 EST

1 comments

This week in cardiology from heartwire

#65: Trials to look for at AHA 2010; Salt: Mandatory limits for most benefits;...

Nov 11, 2010 18:40 EST

Heartfelt with Dr Melissa Walton-Shirley

Gross pics of tobacco carnage: Reverse marketing or empty drama?

Nov 11, 2010 09:21 EST

3 comments

Heart failure and transplantation with Dr Ileana Piña

Heart-failure trials to look for at AHA 2010

Nov 10, 2010 16:35 EST

2 comments

Late-Breaking Trials I
Sunday, November 14, 3:45-5:13PM
Hall B

Download as PDF

	The Resynchronization/Defibrillation for Ambulatory Heart Failure Trial (RAFT) Sunday, November 14, 3:45-3:55 Anthony Tang, University of Ottawa Heart Institute, ON Discussion and panel 3:55-4:07 (Discussant: Clyde Yancy)
	Evaluation of the HeartWare HVAD Left Ventricular Assist Device System for the Treatment of Advanced Heart Failure: Results of the ADVANCE Bridge to Transplant Trial Sunday, November 14, 4:07-4:17 Keith D Aaronson, University of Michigan, Ann Arbor Discussion and panel 4:17-4:29 (Discussant: Magdi Yacoub)
	The Effect of Eplerenone Versus Placebo on Cardiovascular Mortality or Heart Failure Hospitalization in Subjects with NYHA Class II Chronic Systolic Heart Failure (EMPHASIS-HF) Sunday, November 14, 4:29–4:39 Faiez Zannad, INSERM, Université de Nancy, Vandoeuvre-les-Nancy, France Discussion and panel 4:39-4:51 (Discussant: Lynne Warner Stevenson)
	Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF) Sunday, November 14, 4:51-5:01 Adrian F Hernandez, Duke Clinical Research Institute, Durham, NC Discussion and panel 5:01-5:13 (Discussant: Eugene Braunwald)

Late-Breaking Clinical Trials II
Monday, November 15, 10:45AM-12:13PM
Hall B

	Stroke Prevention Using the Oral Direct Factor Xa Inhibitor Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation (ROCKET AF) Monday, November 15, 10:45AM-11:07PM Manesh R Patel for ROCKET AF Executive Steering Committee, Duke University, Durham, NC Discussion and panel 10:55-11:07 (Discussant: Elaine M Hylek)
	Primary Results From the SMART AV Trial: A Randomized Trial Comparing Empiric, Echocardiographic Guided and Algorithmic AV Delay Programming in Cardiac Resynchronization Therapy (CRT) Monday, November 15, 11:07-11:17 Kenneth A Ellenbogen, Medical College of Virginia, Richmond Discussion and panel 11:17-11:29 (Discussant: Christophe Leclercq)
	Efficacy and Safety of Prescription Omega-3-Acid Ethyl Esters (P-OM3) for the Prevention of Recurrent Symptomatic Atrial Fibrillation (AF) Monday, November 15, 11:29-11:39 Peter R Kowey, Main Line Health Heart Center Lankenau Hospital, Wynnewood, PA Discussion and panel 11:39-11:51 (Discussant: Christine Albert)
	CLOSURE I: A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients with a Stroke or Transient Ischemic Attack due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale Monday, November 15, 11:51-12:01 Anthony Furlan, University Hospital Case Neurological Institute, Cleveland, OH Discussion and panel 12:01-12:13 (Discussant: Pierre Amarenco)

Late-Breaking Trials III
Tuesday, November 16, 10:45AM-12:13PM
Hall B

	Standard Versus High-Dose Clopidogrel According to Platelet Function Testing After PCI: Results of the GRAVITAS Trial Tuesday, November 16, 10:45-10:55 Matthew J Price, Scripps Clinic, La Jolla, CA Discussion and panel 10:55-11:07 (Discussant: Jessica L Mega)
	NV1FGF Gene Therapy on Amputation-Free Survival in Critical Limb Ischemia--Phase 3 Randomized Double-Blind Placebo-Controlled Trial Tuesday, November 16, 11:07-11:17 William R Hiatt, University of Colorado Denver Discussion and panel 11:17-11:29 (Discussant: Douglas Losordo)
	Late Cardiac Death and Myocardial Infarction Associated with Late Stent Thrombosis in Large Vessel Stenting After First- or Second-Generation Drug-Eluting Compared to Bare-Metal Stents: The BASKET Prospective Evaluation Examination (BASKET PROVE) Tuesday, November 16, 11:29-11:39 Christoph A Kaiser, University Hospital, Basel, Switzerland Discussion and panel 11:39-11:51 (Discussant: Marco Valgimigli)
	Acetylcysteine for the Prevention of Contrast-Induced Nephropathy (ACT) Trial: A Pragmatic Multicenter Randomized Trial to Evaluate the Efficacy of Acetylcysteine for the Prevention of Renal Outcomes in Patients Undergoing Coronary and Vascular Angiography Tuesday, November 16, 11:51-12:01 Otavio Berwanger, São Paulo Cardiac Hospital, Brazil Discussion and panel 12:01-12:13 (Discussant: Brahmajee K Nallamothu)

Late-Breaking Clinical Trials IV
Wednesday, November 17, 10:45AM-12:13PM
Hall B

	The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT): Testing C-Reactive Protein at Baseline and On-Treatment as an Independent Predictor of Cardiovascular Outcomes Wednesday, November 17, 10:45-10:55 Peter S Sever, Imperial College London, UK Discussion and panel 10:55-11:07 (Discussant: Donald M Lloyd-Jones)
	Primary Results of the DEFINE Trial: Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib Wednesday, November 17, 11:07-11:17 Christopher P Cannon, TIMI Study Group, Boston, MA Discussion and panel 11:17-11:29 (Discussant: Thomas F Luscher)
	Results of the First Major Clinical Trial of an Oral Agent Inducing ApoA1 Synthesis: A New Approach to HDL Raising and CV Risk Modification Wednesday, November 17, 11:29-11:39 Stephen J Nicholls, Cleveland Clinic, OH Discussion and panel 11:39-11:51 (Discussant: Eliot A Brinton)
	Symplicity HTN-2: International, Multicenter, Prospective, Randomized, Controlled Trial of Endovascular Selective Renal Sympathetic Denervation for the Treatment of Hypertension Wednesday, November 17, 11:51-12:01 Murray Esler, Baker IDI Heart and Diabetes Inst, Melbourne, Australia Discussion and panel 12:01-12:13 (Discussant: Suzanne Oparil)